SUBSCRIBE
SUBSCRIBE

Nick Paul Taylor

Nick is a freelance writer who has been reporting on the global life sciences industry since 2008. With a BSc in biology, Nick writes about the science and business of biopharma and medtech for numerous healthcare publications. He can be reached at nick.paul.taylor@gmail.com or on LinkedIn.

A labyrinth maze with a glowing yellow path on a blue background suggesting a concept of problem solving. 3D Rendering
Earnings
Amgen starts MariTide autoinjector study as pivotal readouts approach
With the first Phase 3 data expected for Amgen’s MariTide next year, analysts are looking for evidence that the GLP-1 candidate is tolerable. Meanwhile, the company has begun testing an autoinjector formulation.
November 4, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Vintage Map and Flag of South America, Latin American Countries Series 3D Rendering
Manufacturing
Lonza agrees to buy 5 Merck KGaA facilities to accelerate US expansion
The Swiss contract development and manufacturing organization will more than double its U.S. footprint by acquiring the Merck KGaA plants.
November 3, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Manufacturing
Sun Pharma stops eye-care drug production at Indian plant amid quality issues
The cessation of manufacturing activities follows a Sun Pharma recall and reports that regulators found fault with the company’s quality system.
November 2, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Police officer and sheriff, standing on the egde of the cliff. Handmade painting, acrylic on paper & post processing.
Earnings
Sanofi targets late-phase and commercial M&A to offset looming Dupixent decline
Focused on ensuring growth beyond Dupixent, Sanofi wants to acquire derisked assets that may benefit from the French pharma’s commercial capabilities, executives said on Friday as they reported third-quarter earnings.
October 30, 2026
 · 
2 min read
 · 
Nick Paul Taylor
A 3D rendering of white ceramic mortar and pestle, green medical cross emblem is affixed to the front of bowl. It represents the mixing and grinding raw ingredients.
Manufacturing
HHS clears compounding pharmacies to manufacture 6 unapproved peptides
Under the interim policy, officials do not intend to take action against sites that produce the peptides.
October 29, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Target with three arrows in the bullseye. Close-up version. Vintage style vector illustration.
Cancer
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Analysts hailed the Phase 3 head and neck cancer results as a big victory for an asset central to Genmab’s growth plans.
October 28, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Balance vaccination and anti-vaccination. Vaccination or Anti-vaccination concept, vector illustration
Earnings
GSK vaccine sales miss expectations amid falling demand from adults
With pressure on GSK’s vaccine business, analysts predict the U.K. pharma will face challenges as it prepares for the loss of exclusivity on a key product.
October 28, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Progress 3d bar graph or jumping up steps bar chart with red arrow creative idea concepts isolated on green blue pastel color background with shadow and reflection 3D rendering
Ovarian cancer
Genmab’s ADC beats survival expectations in Phase 3 ovarian cancer trial
Extending both progression-free and overall survival, Genmab’s Rina-S “sets a high bar for future competition” in a market served by AbbVie, analysts said.
October 26, 2026
 · 
2 min read
 · 
Nick Paul Taylor
German flags waving in the wind at famous Reichstag building, seat of the German Parliament (Deutscher Bundestag), on a sunny day with blue sky and clouds, central Berlin Mitte district, Germany.
Policy
Roche flags ‘final opportunity’ for Germany to reestablish as a reliable investment location
Following the withdrawal of billions of dollars in investments from Boehringer Ingelheim and Eli Lilly, German lawmakers have proposed a clause to the country’s healthcare reforms set to take effect Jan. 1.
October 23, 2026
 · 
2 min read
 · 
Nick Paul Taylor
red cyber security protection data from malware attack digital technology map background. vector illustration fantastic technology.
Manufacturing
FDA accuses Baxter leaders of ‘inadequate’ oversight after finding GMP failings
The recurrence of violations at multiple sites led the FDA to conclude that Baxter management must improve its oversight and control of manufacturing.
October 21, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Standing on traditional bathroom scale, measuring one's weight.
Weight loss
Novo’s CagriSema achieves 25% weight loss in women, driven by younger patients
Posthoc analyses in women divided by menopausal status show how Novo’s next-generation GLP-1 drug affects key cohorts of patients.
October 21, 2026
 · 
2 min read
 · 
Nick Paul Taylor
cartoon showing teamwork to build a bridge across a chasm
Pipeline
Epkinly data only one of Genmab’s make-or-break readouts ahead of steep sales erosion
Bracing for patent losses on its cornerstone product Darzalex, Genmab has bet its future on three cancer programs that will deliver pivotal readouts in quick succession.
October 20, 2026
 · 
5 min read
 · 
Nick Paul Taylor
Frankfurt Cathedral in Frankfurt am Main at sunset
Manufacturing
Sanofi breaks ground on insulin plant after securing German government support
The European Commission approved Germany’s financial support after assessing the risks of Sanofi stopping insulin API production at the Frankfurt campus.
October 19, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Illustration of a yellow envelope on a blue background with a read warning symbol
Manufacturing
FDA issues warning over Eurofins’ selective recording that ‘compromises’ data
Inconsistent reporting at a Pennsylvania site affected microbiological analyses of components and drug products that analytical testing service provider Eurofins ran for customers.
October 16, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Flags of US, EU and China painted on cracked wall with people shadow
China
European biotech leaders split on US-China fight for deal dominance, survey finds
While industry leaders are unsure whether the U.S. or China will prevail, they are largely united in the belief that Europe is lagging behind.
October 14, 2026
 · 
2 min read
 · 
Nick Paul Taylor